Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The novel sustained 3-hydroxybutyrate donor poly-D-3-hydroxybutyric acid prevents inflammatory bowel disease through upregulation of regulatory T-cells.
Suzuki R, Mishima M, Nagane M, Mizugaki H, Suzuki T, Komuro M, Shimizu T, Fukuyama T, Takeda S, Ogata M, Miyamoto T, Aihara N, Kamiie J, Kamisuki S, Yokaryo H, Yamashita T, Satoh T. Suzuki R, et al. Among authors: mizugaki h. FASEB J. 2023 Jan;37(1):e22708. doi: 10.1096/fj.202200919R. FASEB J. 2023. PMID: 36562544
Ganglioside GM3 deficiency enhances mast cell sensitivity.
Komuro M, Mizugaki H, Nagane M, Morimoto M, Fukuyama T, Ogihara K, Naya Y, Yokomori E, Kaneshima K, Kawakami Y, Kamiie J, Shibata Y, Suzuki M, Shimizu T, Kawashima N, Okamoto M, Ikeda T, Yamashita T. Komuro M, et al. Among authors: mizugaki h. FEBS J. 2023 Sep;290(17):4268-4280. doi: 10.1111/febs.16806. Epub 2023 May 5. FEBS J. 2023. PMID: 37098812
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S, Sato J, Satouchi M, Itoh S, Okuma Y, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Machida R, Ohe Y, Tamai T, Ikezawa H, Yamamoto N. Niho S, et al. Among authors: mizugaki h. Lung Cancer. 2024 May;191:107557. doi: 10.1016/j.lungcan.2024.107557. Epub 2024 Mar 30. Lung Cancer. 2024. PMID: 38626709 Free article. Clinical Trial.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: mizugaki h. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Ikezawa Y, et al. Among authors: mizugaki h. Cancer Sci. 2022 Jun;113(6):2109-2117. doi: 10.1111/cas.15361. Epub 2022 Apr 15. Cancer Sci. 2022. PMID: 35377496 Free PMC article.
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Mizugaki H, et al. Eur J Cancer. 2022 Jan;160:227-234. doi: 10.1016/j.ejca.2021.10.024. Epub 2021 Nov 30. Eur J Cancer. 2022. PMID: 34862083
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
Ikarashi D, Kitano S, Tsuyukubo T, Takenouchi K, Nakayama T, Onagi H, Sakaguchi A, Yamashita M, Mizugaki H, Maekawa S, Kato R, Kato Y, Sugai T, Nakatsura T, Obara W. Ikarashi D, et al. Among authors: mizugaki h. Br J Cancer. 2022 Mar;126(4):606-614. doi: 10.1038/s41416-021-01628-y. Epub 2021 Nov 15. Br J Cancer. 2022. PMID: 34782748 Free PMC article.
A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
Ito S, Asahina H, Yamaguchi N, Tomaru U, Hasegawa T, Hatanaka Y, Hatanaka KC, Taguchi H, Harada T, Ohira H, Ikeda D, Mizugaki H, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Shinagawa N, Konno S. Ito S, et al. Among authors: mizugaki h. Respir Med Case Rep. 2021 Feb 18;32:101364. doi: 10.1016/j.rmcr.2021.101364. eCollection 2021. Respir Med Case Rep. 2021. PMID: 33665078 Free PMC article.
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
Sakakibara-Konishi J, Sato M, Sato MT, Kasahara K, Onozawa M, Mizugaki H, Kikuchi E, Asahina H, Shinagawa N, Konno S. Sakakibara-Konishi J, et al. Among authors: mizugaki h. Respir Med Case Rep. 2020 Jul 17;31:101170. doi: 10.1016/j.rmcr.2020.101170. eCollection 2020. Respir Med Case Rep. 2020. PMID: 32714828 Free PMC article.
40 results